However, oral semaglutide exists for diabetes treatment, using special absorption enhancers
For a completely different side effect profile, consider bupropion-naltrexone (Contrave)
But if were really talking about treating obesity, those microdosing doses are not going to be effective for most people, and so I worry people are going to pay for it cause its cheaper and then its not going to work for them and theyre going to think heres one more thing thats not working for me. In Diet, Drugs, and Dopamine, former FDA Commissioner David A
The inflammation-marker data
The expected FDA decision on oral semaglutide for obesity (anticipated Q4 2025) is a potential catalyst for further portfolio expansion, market leadership reinforcement, and revenue growth